BD Issues 2021 ESG Report

Company makes notable progress toward 2030+ ESG commitments, addressing energy, water and waste reduction, environmental impact of product portfolio and supplier diversification

FRANKLIN LAKES, N.J., July 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2021 Environmental, Social and Governance (ESG) Report that details ongoing efforts that impact company health, human health, community health and planet health.

"We are taking action to address the most relevant ESG issues for our business and stakeholders, including climate change, diversity, pay equity, transparency and reducing the impact our products have on the environment," said Tom Polen, chairman, chief executive officer and president of BD. "We've made commitments that build on our purpose of advancing the world of health, and true to our culture, we're delivering on those commitments and positioning BD for sustainable growth and resilience."

The report includes the first performance measurements and progress made toward the company's 2030+ ESG commitments, which were unveiled in October 2021. Focusing on key areas where the company looks to create meaningful, measurable change over the next decade, highlights and achievements from this year's report include:  

  • Climate change – BD joined the Race to Zero, committing to scope 1, 2 and 3 greenhouse gas reduction targets in line with 1.5⁰C emissions scenarios to reach science-based net zero emissions by 2050. The company continues to make progress toward its goal of 25% energy reduction by 2030 (from a 2019 baseline, normalized to cost of products sold), achieving 14% energy reduction in FY 2021, in addition to increasing its investment in on-site renewable energy. Currently, 13 BD locations obtain 100% of their electric power from renewable sources.
  • Product impact – BD recently launched a Sustainable Medical Technology Institute to help further reduce the environmental impact of the company's portfolio, set sustainable design standards for products and identify more sustainable sterilization technologies. The company continues to manage end-of-life disposal of products from the BD Pyxis™ portfolio, resulting in 20,771 units processed in FY 2021, which equates to 1,855.15 metric tonnes of material that was refurbished, reused or recycled, with no materials disposed of via landfill.
  • Responsible supply chain – The company spent $565 million with diverse-owned business suppliers and $1 billion with small business suppliers, impacting 2,766 suppliers in total. This reflects an average 33% increase in supplier diversity spend from FY 2020, across all categories of diverse-owned businesses and small business suppliers.
  • Healthy workforce and communities – The company's FY 2021 global pay equity assessment of associates in 57 countries, showed female employees earned 98 cents for every $1 earned by male associates (99 cents in the U.S.), making progress toward the company's commitment to achieve 100% pay equity. [The results showed that BD associates are paid fairly and equitably, and that on average, both women and men are paid within a range that would be expected after controlling for legitimate differentiating factors.] In support of community and human health, BD donated more than $24 million in cash and products worldwide to eligible non-profit organizations to support resilient communities and expand healthcare access and equity. This included $4.1 million in cash and product donations in U.S. free and charitable clinics and community centers, with such contributions totaling $34.5 million since 2009.
  • Transparency – BD published its first Inclusion, Diversity and Equity report and its second Cybersecurity report. The company earned a 100% score on the 2021 corporate political disclosure and accountability index from the Center for Political Accountability, and it was named one of America's Most Responsible Companies and America's Most Trusted Companies by Newsweek. The ESG report also includes disclosures that follow the guidelines of the October 2021 report "Implementing the Recommendations of the Task Force on Climate-related Financial Disclosures."

"We worked with a wide range of stakeholders to drive our strategy and track progress over the last year, which includes launching a Sustainable Medical Technology Institute, joining the Race to Zero, setting science-based targets to help address the worst effects of climate change, and increasing renewable energy sources," said Maureen Mazurek, vice president of Sustainability, Environment, Health and Safety and Product Stewardship at BD. "We developed our 2030+ ESG commitments by focusing our organization where we can make the greatest impact on our industry, people, communities and our planet today. We know this work can make a lasting positive impact, which is why we will continue to challenge ourselves to find opportunities to grow, improve and do what is right."

View the full FY 2021 Environmental, Social and Governance Report on

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws regarding BD's business, strategy, goals, commitments and objectives. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed, projected, anticipated or implied in such statements. All statements, other than statements of historical facts, may be forward-looking statements. Some forward-looking statements may be identified by the use of words such as "plan," "expect," "believe," "intend," "will," "may," "anticipate," estimate," "target," and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and strategy for growth, future product development, regulatory approvals, competitive position, sustainability initiatives and expenditures. Readers should not place undue reliance on forward-looking statements. Forward-looking statements are, and will be, based on management's then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates.

Statements regarding BD's goals, commitments and objectives may include statistics or metrics that are based on estimates and assumptions under developing standards that may change in the future. Such goals and commitments are not intended to be promises or guarantees and actual results may differ, possibly materially. It is not possible to predict or identify all of these risks and uncertainties, many of which are beyond BD's control, including without limitation, challenges relating to economic, competitive, governmental, and technological factors affecting BD's operations, markets, and products, and other factors listed in BD's 2021 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update or revise any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.




Jessica Offerjost
BD Public Relations

Francesca DeMartino

SVP, Head of Investor Relations




Cision View original content to download multimedia:

SOURCE BD (Becton, Dickinson and Company)